Albumin Nanoparticle–Antibody Complexes for Lymphoma Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for lymphomas, such as administering ABRAXANE® and Rituximab separately, do not fully leverage the synergistic potential of albumin-containing nanoparticles and anti-CD20 polypeptide antibodies, resulting in suboptimal efficacy in treating lymphoma.

Innovation Solution

Forming macromolecular complexes of albumin-containing nanoparticles (e.g., ABRAXANE®) with anti-CD20 polypeptide antibodies (e.g., Rituximab) prior to administration, allowing for customized size and composition to enhance chemotherapeutic tumor cell cytotoxicity and target binding specificity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If ABRAXANE and Rituximab are administered separately, then the treatment regimen is simple to implement, but the efficacy in treating lymphoma is suboptimal

Engineering Contradiction:

Improveease of administrationVSAvoidtreatment efficacy

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent combines ABRAXANE (albumin-containing nanoparticles) and Rituximab (anti-CD20 polypeptide antibody) into a single macromolecular complex that can be administered as one formulation. This merging of two separate therapeutic agents into a unified complex maintains ease of administration while significantly improving treatment efficacy through synergistic action and targeted delivery to lymphoma cells.

Inventive Principle:

Principle #5Merging (Combining)

2Ease of operation

If ABRAXANE and Rituximab are administered separately, then the treatment protocol is straightforward, but the progression-free survival rate is limited

Engineering Contradiction:

Improvetreatment protocol simplicityVSAvoidprogression-free survival

Core Design Contradiction:

Ease of operationVSDuration of action of moving object

Solution Approach 1:

The patent performs preliminary action by pre-complexing ABRAXANE with Rituximab before administration. This preliminary formation of the macromolecular complex ensures that both agents are already positioned to work synergistically upon contact with target cells, thereby extending progression-free survival without complicating the administration protocol for the clinician.

Inventive Principle:

Principle #10Preliminary action

3Reliability

If macromolecular complexes are formed, then target binding specificity and tumor cell cytotoxicity are enhanced, but the complexity of the treatment composition increases

Engineering Contradiction:

Improvetarget binding specificityVSAvoidcomposition complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent creates a composite macromolecular complex combining albumin-containing nanoparticles (ABRAXANE) with anti-CD20 polypeptide antibodies (Rituximab). This composite structure integrates the targeted binding capability of the antibody with the chemotherapeutic delivery system of the nanoparticle, enhancing target binding specificity and tumor cell cytotoxicity while presenting as a single therapeutic composition.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS12403119B2Treating lymphomas

Publication Date: 2025.09.02 MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

AI summary

This document provides methods and materials related to treating lymphomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD20 polypeptide antibody complexes) to treat lymphomas are provided.